Table 5.
Incremental Cost-Effectiveness Ratio Analysis of the Tailored Therapies According to the Sequencing-Based Clarithromycin Resistance Test
| Therapy | Tailored BQT* | Tailored MIT* | Empirical CTT |
|---|---|---|---|
| First-line therapy | |||
| Average cost, USD | 169.5 | 166.0 | 117.1 |
| Overall eradication rate, % | 92.2 | 87.5 | 77.4† |
| Incremental cost-effectiveness ratio, USD | 3.5 | 4.9 | - |
| Second-line therapy | |||
| Average cost, USD‡ | 175.9 | 178.2 | 139.0 |
| Overall eradication rate, %‡ | 97.1 | 96.8 | 94.5 |
| Incremental cost-effectiveness ratio, USD | 14.1 | 14.8 | - |
BQT, bismuth-based triple therapy; MIT, metronidazole-intensified triple therapy; CTT, clarithromycin-based triple therapy.
*In the tailored therapy group, patients received the eradication regimen based on the results of the sequencing-based clarithromycin resistance test. CTT was prescribed as the first-line eradication regimen in patients without clarithromycin resistance. For those who showed clarithromycin resistance, BQT or MIT was prescribed as the first-line eradication regimen according to the group assignment; †The first-line eradication rate of empirical CTT was assumed to be 77.4%4; ‡In the cost-effectiveness analysis after second-line therapy, it was assumed that BQT was administered as the second-line rescue therapy in all patients with CTT or MIT failure, and the second-line eradication rate of the BQT was assumed to be 75.5%.4